Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-12-3
|
pubmed:abstractText |
Oligonucleotide-directed triple helix formation represents a promising approach to block gene expression at the transcriptional level. We have previously shown [10] that a triple-helix-forming oligonucleotide was able to inhibit promoter function of reporter constructs in live cells, provided that the oligonucleotide was covalently linked to an intercalating agent which stabilizes triple-helical complexes. In order to demonstrate that this inhibitory effect was due to triple helix formation, we have mutated the oligonucleotide target site in the promoter of the interleukin-2 receptor alpha-chain gene. The mutated version of the promoter does not bind, and is not inhibited by the oligonucleotide, demonstrating that the observed inhibition of the wild-type promoter is indeed due to triple helix formation within cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0764-4469
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
316
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
492-5
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading | |
pubmed:year |
1993
|
pubmed:articleTitle |
Inhibition of interleukin-2 receptor alpha-subunit gene expression by oligonucleotide-directed triple helix formation.
|
pubmed:affiliation |
Laboratoire de Biologie des Tumeurs Humaines, URA 1156, Institut Gustave Roussy, Villejuif, France.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|